Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypophosphatasia (HPP)
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
This clinical trial was conducted to study hypophosphatasia (HPP), a bone disorder caused by
gene mutations or changes. These gene mutations cause low levels of an enzyme needed to
harden bone. The purpose of this study was to test the safety and efficacy of two doses of
the study drug called asfotase alfa as compared to a control group to see effects on
adolescents and adults with HPP.